Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Acriflavine”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1966

Acriflavine-binding capacity of Escherichia coli in relation to acriflavine sensitivity and metabolic activity.

Nakamura, Hakobu (Konan University, Kobe, Japan). Acriflavine-binding capacity of Escherichia coli in relation to acriflavine sensitivity and metabolic activity. J. Bacteriol. 92:1447-1452. 1966.-Inheritance of the acriflavine resistance gene by an acriflavine-sensitive strain of Escherichia coli K-12 resulted in a reduction in the cellular accumulation of acriflavine and other basic dyes, but had no effect on the accumulation of acid dyes. In both acriflavine-resistant and -sensitive strains, the cooling of cells from 37 to 0 C increased acriflavine accumulation. This increased accumulation was released from the cells after restoration to 37 C. Acriflavine accumulation was increased by carbon shortage and by metabolic disturbance caused by potassium cyanide, arsenite, puromycin, chloramphenicol, 2-thiouracil, and 8-azaguanine. The functional relation of acrifiavine accumulation to the acriflavine concentration of the medium suggests that adsorption is involved in the accumulation.

Acridines↗
PubMed2005

Pharmacokinetics and metabolism of acriflavine in rats following intravenous or intramuscular administration of AG60, a mixture of acriflavine and guanosine, a potential antitumour agent.

Acriflavine (ACF; CAS 8063-24-9), a mixture of trypaflavine (TRF) and proflavine (PRF) at a ratio of 2:1 is being investigated in rodents as an anticancer agent. However, its pharmacokinetics have not been investigated in mammals. Guanosine is known to potentiate the anticancer activity of some compounds. The pharmacokinetics of AG60, a 1:1 mixture of ACF and guanosine, were therefore investigated in rats. Rats were given 2 or 10 mg kg(-1) AG60 by intravenous bolus or 6 or 30 mg kg (-1) intramuscularly. An HPLC-based method was developed to analyse the levels of TRF, PRF, and their metabolites in plasma, bile, urine and tissue homogenates. The plasma concentrations of TRF and PRF decreased rapidly after intravenous administration and more slowly after intramuscular administration. Both TRF and PRF were distributed widely, most notably in the kidney, and were eliminated slowly. Three glucuronosyl conjugate metabolite peaks were tentatively identified in the bile. The intramuscular route leads to a prolongation of TRF or PRF plasma levels, and the systemic exposures for both TRF and PRF were both relatively high. These observations indicate that the intramuscular route may be the best way to administer AG60 for various clinical applications.

Acriflavine↗
PubMed1973

Acriflavine uptake and resistance in Serratia marcescens cells and spheroplasts.

Acriflavine uptake and resistance were investigated in red, sensitive Serratia marcescens cells and in orange, resistant mutant cells and their respective spheroplasts. Acriflavine-sensitive cells bound more acriflavine than acriflavine-resistant cells. Spheroplasts from sensitive and resistant cells were both resistant to and bound similar amounts of acriflavine. Sensitive cells were resistant to acriflavine in medium supplemented with 0.01 M MgSO(4) and 0.5 M sucrose. In the presence of 0.01 M MgSO(4) and 0.5 M sucrose, acriflavine binding by sensitive cells was reduced to the level of binding by resistant cells. Inhibition of metabolism by carbon starvation, chloramphenicol, As(2)O(3), nitrosoguanidine, and bromouracil did not affect the uptake of acriflavine by sensitive and resistant cells. Rapid temperature changes did not alter the acriflavine-binding capacity of the cells, and no temperature dependence of acriflavine uptake or release was observed at 0 and 30 C. Acriflavine uptake by both sensitive and resistant cells increased with increase in pH from 5.7 to 8.0. The logarithm of acriflavine uptake was a linear function of the logarithm of the acriflavine concentration in the binding medium.

Acridines↗
PubMed1997

Enhanced anti-tumour effects of acriflavine in combination with guanosine in mice.

The anti-tumour activity of acriflavine in combination with guanosine has been evaluated in solid or ascitic tumour-implanted animal models. Guanosine is known to potentiate the anti-tumour effects of some chemotherapeutic agents. Administration of acriflavine (15 mg kg-1 day-1, i.m., 14 days) to ICR mice subcutaneously implanted with Ehrlich carcinoma resulted in approximately 30% inhibition in tumour growth. In contrast, minor tumour growth inhibition was observed in animals treated with guanosine at the same daily dose. Treatment of animals with both acriflavine and guanosine (AG60, 1:1, w/w) at 30 mg kg-1 resulted in approximately 65% inhibition in tumour growth rate. Whereas treatment with acriflavine or guanosine resulted in 70% or 30% decrease in tumour weight, respectively, treatment of tumour-implanted mice with AG60 (30 mg kg-1) resulted in a 96% decrease in tumour weight, relative to control, 14 days after tumour-cell implantation. Dose-related inhibition in tumour growth rate was also observed in animals treated with AG60, with maximum (65%) inhibition noted at a dose of 30 mg kg-1 (ED50 23 mg kg-1). Suppression of body weight increase and elevated plasma glucose levels by acriflavine or AG60 indicated that glucose utilization might be impaired. The anti-tumour effect of AG60 was also determined in CDF1 mice intraperitoneally implanted with Ehrlich ascitic tumour. Ehrlich ascitic tumour proliferation was completely suppressed by AG60 (30 mg kg-1, i.p.). Microscopic analyses of intraperitoneal touch-prints revealed that AG60 was more effective in suppressing tumour proliferation than acriflavine alone. Fluorescent microscopic examinations demonstrated that acriflavine avidly bound with Yac-1 cell plasma membrane, leading to morphological changes in the cells, such as bleb formations, swelling and ballooning. The time-related changes in tumour cell morphology by acriflavine or AG60 might represent energy depletion, followed by osmotic lysis as a result of cationic influx. Enhanced anti-tumour activity of acriflavine in combination with guanosine might be explained by the blocking of nutrient transport through selective acriflavine binding with plasma membrane and by concomitant guanosine perturbation of cellular ATP production. This study demonstrates that guanosine enhances the anti-tumour effects of acriflavine against a variety of cancer cells without serious adverse effects, providing a preclinical basis for potential application of this combination against cancer proliferation.

Acriflavine↗
PubMed1985

Acriflavine-binding capacity controlled by the acrA gene of Escherichia coli.

The acrA mutation in Escherichia coli led to a substantial increase of the acriflavine-binding capacity of the cell, whereas the related mutations acrB (gyrB) and arcC did not. Metal ions such as Na+, K+, Mg2+, Ca2+ and Al3+ effectively released the bound acriflavine, in proportion to their ionic strengths. The presence of cations, in fact, increased the survival fraction of the cells in the acriflavine-containing medium. Polymyxin B, an antibiotic which binds to membrane phospholipid, competed with acriflavine for binding sites. Cell wall digestion by treatment with lysozyme and EDTA slightly decreased the acriflavine-binding capacity. Almost no difference was observed in acriflavine-binding capacity between intact cells and cells from which lipopolysaccharide has been extracted (46.9% removed from the acrA cells and 47.4% from the acrA+ cells). Acriflavine bound to the cells was most effectively extracted by ethanol containing 1% HCl or by 2% (w/v) SDS. The difference in the acriflavine-binding capacity between the acrA and acrA+ cells was also observed in the spheroplasts. These facts indicate a relationship between the acrA gene product and the acriflavine-binding capacity of the cells.

Acriflavine↗
PubMed1980

Mutation to acriflavine resistance in some myxobacteria.

In contrast to other Gram-negative bacteria, several species of fruiting Myxobacteria were found to be extremely sensitive to acriflavine. Depending on the species, acriflavine concentrations of 0.05 to 0.5 micrograms affected growth rate and viability. Spontaneous first-step mutants resistant to acriflavine were isolated. Most of these mutants were cross-resistant to both proflavine and ethidium bromide. Some mutants, however, were not cross-resistant to the latter dye. In two species it was possible to select second-step mutants showing increased resistance to acriflavine. First-step acriflavine-resistant mutants, not cross-resistant to ethidium bromide, acquired cross-resistance to this latter dye as a result of the second mutation. However, in some mutants the second mutation enhancing resistance to acriflavine partially abolished resistance to ethidium bromide. The mechanisms of resistance are not yet known. Resistance in one mutant of a Cystobacter strain is probably not caused by inhibition of acriflavine uptake into the cell. It is possible that more than one gene could be responsible for acriflavine resistance, and that the acriflavine sensitivity of wild-type strains may indicate a higher permeability of the outer membrane of Myxobacteria compared with other Gram-negative bacteria. This high permeability could be a prerequisite for the cell-cell interactions necessary for gliding motility and morphogenesis.

Acridines↗
PubMed1998

Evaluation of an acriflavine disk assay for differentiating Staphylococcus aureus from other staphylococci isolated from bovine milk.

OBJECTIVE: To develop an acriflavine disk assay for identification of Staphylococcus aureus and to test whether the acriflavine disk assay could be used to differentiate S aureus from other staphylococci isolated from bovine milk samples. DESIGN: Prospective study. SAMPLE POPULATION: 882 staphylococcal isolates from bovine milk samples and 3 S intermedius isolates from dogs. PROCEDURE: Paper disks saturated with various amounts of acriflavine were used in a growth inhibition assay to determine the amount of acriflavine that would most reliably differentiate S aureus from other staphylococci. For all isolates, hemolytic pattern, results of tube coagulase tests after 4 and 24 hours of incubation, growth on acriflavine-supplemented media, results of an acriflavine disk assay, and results of an automated identification system were determined. RESULTS: 10 micrograms of acriflavine/disk was determined to be the most appropriate concentration for use in the assay. All 112 isolates identified as S aureus by the automated identification system were resistant to this concentration of acriflavine, and only 1 of 236 isolates identified as non-S aureus staphylococci was resistant. There was substantial agreement between results of using the acriflavine disk assay as a diagnostic criterion for differntiating S aureus isolates from non-S aureus staphylococci and results of the automated identification system. Agreement between results of determining hemolytic pattern and results of other diagnostic tests was only moderate. CLINICAL IMPLICATIONS: The acriflavine disk assay, using 10 micrograms of acriflavine/disk, was a practical, accurate method for differentiating S aureus isolates from non-S aureus staphylococci.

Acriflavine↗
PubMed1976

Fluorescent labeling of DNA in solution with covalently bound acriflavin.

We have prepared a fluorescent derivative of DNA based on the acriflavin-Feulgen histological procedure for staining DNA. Our procedure involved binding acriflavin to DNA in solution by reacting the acriflavin with aldehydes formed on the deoxyribose of DNA by controlled removal of a few percent of the purine bases of the DNA. Partially depurinated DNA was reacted with the acriflavin reagent, and unbound acriflavin was removed by chromatography on Sephadex G-25 eluted with phosphate buffered guanidine -HCl. Such single-stranded depurinated DNA bound 0.36 acriflavin molecules per 100 purine bases per h of depurination. DNA containing one bound acriflavin per 200 bases reassociated at 85% of the value of control DNA. The acriflavin - DNA complex showed new absorption maxima at 466 and 370 nm. The fluorescent product had excitation maxima at 304 and 465 nm and an emission maximum at 502 nm. This labeling procedure should be useful in place of or in addition to radioactive labeling for DNA.

Acridines↗
PubMed1968

Genetic determination of resistance to acriflavine, phenethyl alcohol, and sodium dodecyl sulfate in Escherichia coli.

Wild-type strains of Escherichia coli K-12 are resistant to acriflavine. Gene acrA(+) which determines resistance to acriflavine is located near the lac region of the chromosome. This gene determines not only resistance to basic dyes but also resistance to phenethyl alcohol. Acriflavine resistance was transmitted, together with phenethyl alcohol resistance, from a resistant Hfr strain to a sensitive recipient by mating. Reversion of the mutant gene acrA1 (phenotypically acriflavine-sensitive) to acriflavine resistance was accompanied by a change from phenethyl alcohol sensitivity to resistance, and conversely the revertants selected for phenethyl alcohol resistance were resistant to acriflavine. A suppressor mutation, sup-100, closely linked to the acr locus, suppresses the acrA1 gene (phenotypically acriflavine-resistant), but does not determine resistance to phenethyl alcohol and basic dyes other than acriflavine. The genetic change in the locus acrA1 to types resistant to basic dyes and phenethyl alcohol was accompanied by an increase in resistance to sodium dodecyl sulfate, a potent solvent of lipopolysaccharide and lipoprotein. It is suggested that gene acrA determines synthesis of a membrane substance. The system seemed to be affected strongly by the presence of inorganic phosphate.

Acridines↗
PubMed2006

Selective growth of Staphylococcus aureus from flushed dairy manure wastewater using acriflavine-supplemented mannitol salt agar.

AIMS: To investigate the use of mannitol salt agar (MSA) supplemented with acriflavine for selective growth and quantification of Staphylococcus aureus from flushed dairy manure wastewater (FDMW). METHODS AND RESULTS: Minimal inhibitory concentrations of acriflavine in MSA were determined by comparing the growth of S. aureus subsp. aureus (ATCC 33591) and Staphylococcus epidermidis (ATCC 155) in pure culture. Acriflavine concentrations of 1.3, 1.4 and 1.5 mg l(-1) reduced CFU of S. epidermidis by 43%, 55% and 87%, respectively, while CFU of S. aureus subsp. aureus were only reduced by 15%, 20% and 26% at the respective concentrations of acriflavine. MSA supplemented with 1.5 mg l(-1) acriflavine was tested for selective growth of indigenous S. aureus from three grab samples of FDMW. Acriflavine concentrations of 1.5 mg l(-1) reduced background flora without significantly reducing (P < 0.05) indigenous S. aureus counts. CONCLUSIONS: Acriflavine-supplemented MSA provides an effective media for selective growth and quantification of indigenous S. aureus from FDMW in the presence of high levels of background microflora. SIGNIFICANCE AND IMPACT OF THE STUDY: S. aureus is implicated for mastitis infections in dairy cows. Therefore, a reliable means for monitoring and detecting the organism in FDMW provides a tool for measuring the effectiveness of treatment for reducing S. aureus levels and implementing flushwater recycling without affecting herd health.

Acriflavine↗
PubMed1978

An improved acriflavine-Feulgen reagent for quantitative DNA cytofluorometry.

We have modified the acriflavine-Feulgen histochemical method for the quantitative determination of DNA by performing the staining of hydrolyzed cells affixed to cover slips with acriflavine dissolved in 90% ethanol. Compared to conventional techniques, in which the acriflavine is dissolved in aqueous HCl plus potassium metabisulfite, this method not only decreased non-Feulgen (background) staining in both the nucleus and the cytoplasm, but also increased the fluorescent intensity of Feulgen stained nuclei more than four-fold. Cells stained by our modified method exhibited a fluorescence maximum of 507 nm, which is similar to the 500 nm fluorescence maximum obtained with acriflavine bound to apurinic acid solution by a modification of the acriflavine-Feulgen method. These fluorescence maxima are in contrast to the 510 nm to 625 nm fluorescence maxima which are obtained when cells are stained according to conventional protocols. The fluorescence intensities of nuclei of synchronized cells stained by the modified method were proportional to DNA content. Thus, by the criteria of staining specificity, in situ and in solution fluorescence spectra agreement and quantitative staining, we conclude that our modified acriflavine-Feulgen method is more satisfactory for quantitatively measuring DNA in situ by cytofluorometry than the usual acriflavine-Feulgen method.

Acriflavine↗
PubMed1979

Model studies on the acriflavine-Feulgen reaction.

The specificity and quantitative reliability of the Feulgen-acriflavine-SO2 procedure was tested on polyacrylamide model films containing DNA. Noncovalent binding of acriflavine to DNA was observed when the washing procedure, as used in the classical way, was applied. The noncovalently bound acriflavine could be removed with an extra wash in acid-ethanol. The presence of SO2 in the staining solution has been found to enhance covalent binding significantly. The absorbance of films stained by our Feulgen-acriflavine-SO2 procedure is directly proportional to that obtained by the classical Feulgen-pararosanilline-SO2 procedure. The acriflavine-Feulgen procedure has also been tested using a commercial and a purified dye. The use of purified acriflavine, compared to a commercial sample did not result in a significant difference in the maximum absorbance value of stained DNA nor in the absorption or the fluorescence emission spectra of acriflavin covalently bound to DNA.

Acriflavine↗
PubMed1972

Membrane mutation associated with sensitivity to acriflavine in Escherichia coli.

The role of plasma membrane on the acriflavine sensitivity of Escherichia coli was studied. (14)C-uracil incorporation into ribonucleic acid fraction by spheroplasts was more sensitive to acriflavine in the acriflavine-sensitive strain (genotype acrA) than in the acriflavine-resistant (genotype acrA(+)) strain. There was no difference between two types of cells in the response to osmotic shock, phage sensitivity, and other treatments used to investigate the structure and stability of cell wall. Differences in the electron-microscopic figures between acrA and acrA(+) cells was found in the plasma membrane, surface area just below the membrane, and ribosomal aggregation, when cells were treated with acriflavine. It is concluded that a primary site of acriflavine action is on the plasma membrane, and the acrA mutation is mediated by it. On the basis of the present results, it is evident that differences in the acriflavine binding and the sensitivity to phenethyl alcohol and sodium dodecyl sulfate between the acrA and acrA(+) strains, previously reported, are attributable to a structural difference in the plasma membrane between the two strains.

Acridines↗
PubMed1984

Human blood platelet secretion: optical multichannel analyzer measurements using acriflavine as a release indicator.

Blood platelets preloaded with the fluorescent amine acriflavine release the trapped fluorophore after stimulation with thrombin or the divalent cation ionophore A23187. Release was detected by an increase in acriflavine fluorescence, which is otherwise strongly quenched in the platelet, by using an optical multichannel analyzer to monitor the spectral and temporal reaction parameters. The secretion of [14C]serotonin and acriflavine is well correlated, suggesting that acriflavine, like serotonin and the closely related fluorescent drugs mepacrine and acridine orange, is accumulated in and released from platelet dense bodies. Acriflavine secretion at 37 degrees C in the absence of external calcium is characterized by a short delay, followed by a rapid biphasic increase in fluorescence that implies at least a three-stage secretory process. For saturating levels of thrombin the delay was 1.5 s and release was 90% complete within 6-7 s. The delay could not be shortened by prestimulation under conditions that induce shape changes but not release, i.e., with ADP, arachidonic acid, or low levels of thrombin or A23187. Acriflavine secretion induced by A23187 was similar but less effective; the reaction was slower, the yield was smaller, and, in contrast to thrombin, the longer lag period could be significantly shortened by prestimulation.

Acriflavine↗
PubMed1982

Effect of acriflavine on the plasma membrane of Escherichia coli K12.

Plasma membranes of acriflavine-sensitive mutant (acrA) and acriflavine-resistant (acrA+, wild-type and true revertant) Escherichia coli K12 strains treated with acriflavine were observed under the electron microscope by means of the freeze-fracture technique. The plasma membrane of the acrA mutant exhibited a complex lamellar structure at the end of the cell when treated with 20 micrograms acriflavine ml-1. However, the membrane of the acrA+ cells also gave the lamellar complex when treated with a very high concentration of acriflavine (100 micrograms ml-1). The size of the intramembranous particles was not affected by the acriflavine treatments.

Acriflavine↗